biostudies-literatureUnknown63(1)Pett SLViiV Healthcare and Pfizer LtdThe Kirby Institute<h4>Background</h4>Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.<h4>Methods</h4>The Maraviroc Switch Study is a randomized, multicenter, 96-week, open-label switch study in HIV type 1-infected adults with R5-tropic virus, virologically suppressed on a ritonavir-boosted protease inhibitor (PI/r) plus double nucleoside/nucleotide reverse transcriptase inhibitor (2 N(t)RTI) backbone. Participants were randomized 1:2:2 to current combination antiretroviral therapy (control), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America122-32https://www.ebi.ac.uk/biostudies/studies/S-EPMC5853584biostudies-literatureMaraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.PMC5853584Pett SSirivichayakul SWadham SMaek-A-Nantawat WTarga MCuprasitrut TAssam DParedes RBelloso WSandhu RGonzalez LMontes de Oca MLuebke NTaylor JDonohue WGutierrez MDelgado-Fernandez MChibo DStephan CRahal IPrazuck TEbeling FWalker SFisher MGibson ATabrett CPorteiro NLuchetti PSimelane SLand SBaumgarten APuig JElliot JSpath BStein JBirch CMaraviroc Switch (MARCH) Study GroupVieni ILopez MSchuelter ERismanto NImamura JCorr SIwatani YMejia RStoll MHorban ABerg TBissio EJaisomkom PVincent TRamon Arribas JDrummond FIntasan JBeleta HWarzywoda EMurray SWinston AMurray TThompson JDeJesus EGill JGonzalez-Cordon AZedlack CBeider RTu EJessen HSanz-Moreno JWolff MRuxrungtham KGambardella LSierra Madero JSanchez Hernandez JEWoolley ISugiura WHagenauer MSowden DRivas ISilk DCoughlan SReko TMeyer-Olson DWolfgang JRockstroh JSuzuki KLeen CSierra-Madero JRubio AEMorris SLopez Aldeguer JFsadni BAvila SValdovinos MGhavami-Kia BYeung JDel Moral Ponce SHalpenny RItaliano HMallon PMarks KThomas Baumgarten ELosso MTanabe KSinn KDean JNaphassanant MBarbour LEmery SLefevre ERobson RClark ARowling DSanchez MWarley EChan WSinclair BStewart NFox JDomingo PBerthon-Jones NCourtney-Vega KSalomon HLatch NWalmsley SCharoenporn WJohnston CPonce DChan DArnaiz JIngiliz PPeroni LJaime Ruiz Ballesteros EOzturk SMerlin KGarsia RLeal Noval MKaye SAbsar NObermeier MMacRae KAmin JBehrendt DKelleher ASatyajit DOrth DRichardson CHaskelberg HKaiser RArnaiz JAKelley MAssmann JYouds DRamos NSierra Aragon SLanteigne FEngelhardt AGatell JHoeper KZarate ABryant MReyes Teran GCallau PMosqueda LClarke AHehir JViloria GKok JPulik PRobinette Hills JFaetkenheur GFeind CMendoza AMadden TMullaney SGuber SDwyer DUbolyam SImahashi MDe Paz Sierra MBeckthold BNienkarken TFranic TRockstroh JKTurnham GPruksakaew KLaurent Hocqueloux FDonaldson AEspinosa NMayer GLupo SGillies AMouawad RKing PHaubrich RWienbreyer AMiguel Castro JParlante AGuelman DSwenson LIgnatowska ABloch MPett SLSmith GVilas CBoesecke CJayewardene AGrant COle Jensen BECooper DPerry NBakowska ELeBlanc RAvihingsanon AHarrigan RYokomaku YCuellar Tovar STucker JAndrade-Villanueva JfalseMaraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.<h4>Background</h4>Alternative combination antiretroviral therapies in virologically suppressed human immunodeficiency virus (HIV)-infected patients experiencing side effects and/or at ongoing risk of important comorbidities from current therapy are needed. Maraviroc (MVC), a chemokine receptor 5 antagonist, is a potential alternative component of therapy in those with R5-tropic virus.<h4>Methods</h4>The Maraviroc Switch Study is a randomized, multicenter, 96-week, open-label switch study in HIV type 1-infected adults with R5-tropic virus, virologically suppressed on a ritonavir-boosted protease inhibitor (PI/r) plus double nucleoside/nucleotide reverse transcriptase inhibitor (2 N(t)RTI) backbone. Participants were randomized 1:2:2 to current combination antiretroviral therapy (control), 2016-01-01T00:00:00Z2016 Jul2025-04-18T11:49:27.167Z2019-06-06T19:08:14ZS-EPMC58535842704874710.1093/cid/ciw207